Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Indian market for these drugs has grown to nearly Rs 600 crore and is expected to keep growing. Weight-loss drugs are ...

More than a dozen lawsuits have been filed on behalf of weight-loss drug users who claim that popular weight-loss medications ...

Learning to accept that bipolar makes up one irrefutable aspect of identity — just like nearsightedness, allergies, or introversion — nurtures a healthier self-image and ... negative labels. The list ...

In a statement, Ro said it will make Zepbound available as a treatment option with an on-label prescription from a Ro-affiliated provider that will be integrated with the LillyDirect self-pay ...

The Food and Drug Administration is cracking down on copycat versions of Ozempic — the brand name of semaglutide — and Zepbound — the brand name of tirzepatide, threatening a workaround that allowed ...

Sleep Token previously peaked at No.16 in the US with Take Me Back To Eden in 2023. It has amassed 819,000 units in the US to date.

Ozempic made headlines. Now its maker faces stock crashes, CEO fallout, and fierce rivalry from Eli Lilly. Discover the trade behind the drama.